C. Turesson

发表

Cardiovascular co-morbidity in rheumatic diseases

C. Turesson, L. Jacobsson, E. Matteson, 2008, Vascular health and risk management.

The risk of clinically diagnosed gout by serum urate levels: results from 30 years follow-up of the Malmö Preventive Project cohort in southern Sweden

P. Nilsson, C. Turesson, L. Jacobsson, 2018, Arthritis Research & Therapy.

Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?

M. Neovius, C. Turesson, M. Englund, 2017, Annals of the rheumatic diseases.

Extra-articular rheumatoid arthritis: prevalence and mortality.

C. Turesson, L. Jacobsson, U. Bergström, 1999, Rheumatology.

Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?

C. Turesson, K. Pavelka, M. Santos, 2019, RMD Open.

A high body mass index is associated with reduced risk of rheumatoid arthritis in men, but not in women.

C. Turesson, L. Jacobsson, J. Nilsson, 2016, Rheumatology.

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

H. Olsson, C. Turesson, P. Geborek, 2005, Annals of the rheumatic diseases.

EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries

Y. van Eijk-Hustings, M. D. de Wit, A. Woolf, 2020, Annals of the Rheumatic Diseases.

Smoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis

C. Turesson, I. Petersson, L. Jacobsson, 2005, Annals of the rheumatic diseases.

Smoking, body mass index, disease activity, and the risk of rapid radiographic progression in patients with early rheumatoid arthritis

C. Turesson, L. Jacobsson, J. Nilsson, 2018, Arthritis Research & Therapy.

The presence of rheumatoid nodules at early rheumatoid arthritis diagnosis is a sign of extra-articular disease and predicts radiographic progression of joint destruction over 5 years

C. Turesson, I. Petersson, J. Nilsson, 2011, Scandinavian journal of rheumatology.

High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis.

C. Turesson, I. Petersson, J. Nilsson, 2009, Rheumatology.

Is atherosclerosis in rheumatoid arthritis related to disease severity and extraarticular manifestations? Comment on the article by Chung et al.

C. Turesson, E. Matteson, 2006, Arthritis and rheumatism.

Pulmonary dysfunction, smoking, socioeconomic status and the risk of developing rheumatoid arthritis.

G. Berglund, C. Turesson, L. Jacobsson, 2011, Rheumatology.

Incidence and prevalence of giant cell arteritis and polymyalgia rheumatica: A systematic literature review.

C. Turesson, Ankita Sharma, A. Mohammad, 2020, Seminars in arthritis and rheumatism.

Infections Are Associated With Increased Risk of Giant Cell Arteritis: A Population-based Case-control Study from Southern Sweden

C. Turesson, G. Jönsson, M. Englund, 2020, The Journal of Rheumatology.

Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Population-based Study

P. Merkel, C. Turesson, M. Englund, 2016, The Journal of Rheumatology.

2018 Update of the EULAR recommendations for the management of large vessel vasculitis

C. Turesson, F. Buttgereit, G. Hatemi, 2019, Annals of the rheumatic diseases.

The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis

C. Turesson, L. Jacobsson, E. Matteson, 2016, BMC Musculoskeletal Disorders.

Biopsy findings in giant cell arteritis: relationship to baseline factors and corticosteroid treatment

C. Turesson, L. Jacobsson, K. Warrington, 2013, Scandinavian journal of rheumatology.

Swedish Society of Rheumatology 2018 guidelines for investigation, treatment, and follow-up of giant cell arteritis

C. Turesson, A. Knight, O. Börjesson, 2019, Scandinavian journal of rheumatology.

Evaluation of revised classification criteria for giant cell arteritis and its clinical phenotypes

C. Turesson, Frans Wiberg, A. Mohammad, 2021, Rheumatology.

Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study

P. Merkel, C. Turesson, M. Englund, 2017, The Journal of Rheumatology.

Large vessel involvement in biopsy-proven giant cell arteritis: incidence, distribution, and predictors

C. Turesson, N. Naderi, Ajith Mohammad, 2017, Scandinavian journal of rheumatology.

Body mass index and the risk of giant cell arteritis: results from a prospective study.

O. Melander, C. Turesson, L. Jacobsson, 2015, Rheumatology.

Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers

C. Turesson, L. Jacobsson, S. Rantapää-Dahlqvist, 2016, Annals of the rheumatic diseases.

Proceedings of the Combined Scientific Meeting of the New Zealand Rheumatology Association and the Australian Rheumatology Association with the New Zealand Health Professionals in Rheumatology and the Rheumatology Health Professionals Association of Australia ‐ 2002

C. Turesson, C. Crowson, M. O'Fallon, 2003 .

Giant cells in temporal artery biopsies are associated with a reduced risk of large vessel involvement in patients with giant cell arteritis : a retrospective cohort study

C. Turesson, J. Nilsson, A. Mohammad, 2020 .

Cigarette smoking and the risk of primary Sjögren’s syndrome: a nested case control study

C. Turesson, L. Jacobsson, E. Theander, 2017, Arthritis Research & Therapy.

Early menopause is an independent predictor of rheumatoid arthritis

C. Turesson, L. Jacobsson, J. Nilsson, 2011, Annals of the rheumatic diseases.

Increased cartilage turnover and circulating autoantibodies in different subsets before the clinical onset of rheumatoid arthritis

G. Berglund, C. Turesson, L. Jacobsson, 2010, Annals of the rheumatic diseases.

Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden—an update on incidence and first prevalence estimate

C. Turesson, M. Englund, A. Turkiewicz, 2021, Rheumatology.

Clustering of extraarticular manifestations in patients with rheumatoid arthritis.

C. Turesson, E. Matteson, R. McClelland, 2008, The Journal of rheumatology.

modi fi cations of the Ca 2 + release complex and actin underlie arthritis-induced muscle weakness

H. Westerblad, C. Turesson, F. Minozzo, 2015 .

The absolute risk of gout by clusters of gout-associated comorbidities and lifestyle factors—30 years follow-up of the Malmö Preventive Project

P. Nilsson, C. Turesson, L. Jacobsson, 2020, Arthritis Research & Therapy.

Incidence and predictors of severe extra-articular disease manifestations in an early rheumatoid arthritis inception cohort

C. Turesson, E. Lindqvist, K. Eberhardt, 2007, Annals of the rheumatic diseases.

Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset

Pall I. Olason, H. Stefánsson, D. Gudbjartsson, 2022, Annals of the Rheumatic Diseases.

Autoantibodies in Rheumatoid Arthritis – Laboratory and Clinical Perspectives

C. Turesson, A. Kastbom, J. Rönnelid, 2021, Frontiers in Immunology.

Predictors of unacceptable pain with and without low inflammation over 5 years in early rheumatoid arthritis—an inception cohort study

C. Turesson, L. Jacobsson, S. Bergman, 2021, Arthritis Research & Therapy.

Predictors of radiographic erosion and joint space narrowing progression in patients with early rheumatoid arthritis: a cohort study

C. Turesson, L. Jacobsson, J. Nilsson, 2020, Arthritis Research & Therapy.

Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis

C. Allaart, C. Turesson, L. Jacobsson, 2020, Arthritis & rheumatology.

Multiplex cytokine analyses in patients with rheumatoid arthritis require use of agents blocking heterophilic antibody activity

C. Turesson, E. Theander, S. Jovinge, 2017, Scandinavian journal of rheumatology.

Severe Extraarticular Manifestations in a Community-based Cohort of Patients with Rheumatoid Arthritis: Risk Factors and Incidence in Relation to Treatment with Tumor Necrosis Factor Inhibitors

C. Turesson, L. Jacobsson, I. Petersson, 2017, The Journal of Rheumatology.

High serum cholesterol predicts rheumatoid arthritis in women, but not in men: a prospective study

C. Turesson, L. Jacobsson, J. Nilsson, 2015, Arthritis Research & Therapy.

Parity influences the severity of ACPA-negative early rheumatoid arthritis: a cohort study based on the Swedish EIRA material

C. Turesson, L. Alfredsson, L. Klareskog, 2015, Arthritis Research & Therapy.

Changes and sex differences in patient reported outcomes in rheumatoid factor positive RA–results from a community based study

C. Turesson, L. Jacobsson, J. Nilsson, 2014, BMC Musculoskeletal Disorders.

Association between testosterone levels and risk of future rheumatoid arthritis in men: a population-based case–control study

C. Turesson, L. Jacobsson, A. Giwercman, 2013, Annals of the rheumatic diseases.

Decrease in the incidence of total hip arthroplasties in patients with rheumatoid arthritis - results from a well defined population in south Sweden

G. Garellick, C. Turesson, L. Jacobsson, 2011, Arthritis research & therapy.

Delays in assessment of patients with rheumatoid arthritis: variations across Europe

C. Turesson, S. Rantapää-Dahlqvist, H. Mann, 2011, Annals of the rheumatic diseases.

CHAPTER 5B – Clinical Features of Rheumatoid Arthritis: Extra-Articular Manifestations

C. Turesson, E. Matteson, 2009 .

Malignancies in Giant Cell Arteritis: A Population-based Cohort Study

C. Turesson, M. Englund, J. Nilsson, 2020, The Journal of Rheumatology.

Chapter 4 – Management of Rheumatoid Arthritis: The Patient with Extra-Articular Disease

C. Turesson, 2010 .

Male Sex Predicts a Favorable Outcome in Early ACPA-Negative Rheumatoid Arthritis: Data From an Observational Study

C. Turesson, M. Compagno, A. Eberhard, 2022, The Journal of Rheumatology.

Effects of the COVID-19 pandemic on patients with inflammatory joint diseases in Sweden: from infection severity to impact on care provision

C. Turesson, Lars Klareskog, J. Askling, 2021, RMD Open.

The impact of patient heterogeneity and socioeconomic factors on abatacept retention in rheumatoid arthritis across nine European countries

C. Turesson, P. V. van Riel, X. Mariette, 2015, RMD Open.

The Journal of Rheumatology Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study

C. Turesson, M. Englund, G. Tómasson, 2016 .

Smoking, disease characteristics and serum cytokine levels in patients with primary Sjögren’s syndrome

C. Turesson, E. Theander, G. Houen, 2018, Rheumatology International.

Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries

C. Turesson, J. Askling, B. Delcoigne, 2022, Annals of the Rheumatic Diseases.

The impact of obesity on the development and progression of rheumatoid arthritis

C. Turesson, A. Finckh, 2014, Annals of the rheumatic diseases.

Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data

C. Turesson, J. Askling, A. Kastbom, 2022, Rheumatology.

Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register.

R. Nisell, C. Turesson, S. Rantapää-Dahlqvist, 2019, Rheumatology.

Mortality in ankylosing spondylitis: results from a nationwide population-based study

C. Turesson, L. Jacobsson, J. Askling, 2015, Annals of the rheumatic diseases.

Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study

C. Turesson, L. Jacobsson, L. Jacobsson, 2004, Annals of the rheumatic diseases.

Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice

C. Turesson, Lars Klareskog, J. Askling, 2021, Rheumatology.

SAT0369 EQ-5D Utility, Response and Drug Adherence in Rheumatoid Arthritis Patients on Biologic Monotherapy: A Prospective Observational Study of Patients Registered in the South Swedish SSATG Registry

C. Turesson, H. Bliddal, M. Englund, 2015 .

Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the “pan-European registry collaboration for abatacept (PANABA)

C. Turesson, X. Mariette, K. Pavelka, 2017, Clinical Rheumatology.

Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sjögren’s syndrome

C. Turesson, E. Theander, M. Versnel, 2019, Rheumatology International.

THU0135 The course of lower extremity function in patients with early rheumatoid arthritis over the first five years

C. Turesson, L. Jacobsson, C. Book, 2017 .

Lifestyle Factors and Disease Activity Over Time in Early Axial Spondyloarthritis: The SPondyloArthritis Caught Early (SPACE) Cohort

R. Landewé, C. Turesson, H. Dagfinrud, 2021, The Journal of Rheumatology.

No decrease over time in the incidence of vasculitis or other extraarticular manifestations in rheumatoid arthritis: results from a community-based study.

C. Turesson, E. Matteson, R. McClelland, 2004, Arthritis and rheumatism.

Pathogenesis of giant cell arteritis with focus on cellular populations

C. Turesson, D. Michailidou, A. Mohammad, 2022, Frontiers in Medicine.

Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden

P. Merkel, C. Turesson, L. Jacobsson, 2014, Annals of the rheumatic diseases.

A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission

C. Turesson, E. Lindqvist, R. Vollenhoven, 2012 .

C. Turesson, L. Jacobsson, M. Rydholm, 2020 .

Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study

C. Turesson, Lars Klareskog, J. Askling, 2021, Annals of the Rheumatic Diseases.

Extra-articular manifestations in a community-based sample of patients with rheumatoid arthritis: incidence and relationship to treatment with TNF inhibitors

C. Turesson, P. Geborek, I. Petersson, 2012, Scandinavian journal of rheumatology.

Guidelines for the Pharmaceutical Management of Rheumatoid Arthritis

C. Turesson, E. Baecklund, H. F. d’Elia, 2012 .

Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years

S. Gabriel, W. O'Fallon, C. Turesson, 2003, Annals of the rheumatic diseases.

Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years.

S. Gabriel, H. Kremers, W. O'Fallon, 2003, Arthritis and rheumatism.

Epidemiology of extra‐articular manifestations in rheumatoid arthritis

C. Turesson, L. Jacobsson, 2004, Scandinavian journal of rheumatology.

The role of testosterone and other hormonal factors in the development of rheumatoid arthritis

C. Turesson, M. Pikwer, 2014 .

Genetics of rheumatoid arthritis.

C. Turesson, E. Matteson, 2006, Mayo Clinic proceedings.

Occurrence of extraarticular disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis.

S. Gabriel, W. O'Fallon, C. Turesson, 2002, The Journal of rheumatology.

Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis

C. Turesson, L. Jacobsson, E. Matteson, 2020, Rheumatology.

Effects of adalimumab treatment on endothelial cell activation markers in the skeletal muscle of patients with rheumatoid arthritis.

C. Turesson, L. Jacobsson, I. Lundberg, 2014, Clinical and experimental rheumatology.

Intracranial manifestations in SAPHO syndrome: the first case report in literature

C. Turesson, K. Abul-Kasim, Tomas Nilsson, 2012, Rheumatology International.

Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis

C. Allaart, C. Turesson, T. Huizinga, 2021, Arthritis & Rheumatology (Hoboken, N.j.).

Multiple extra-articular manifestations are associated with poor survival in patients with rheumatoid arthritis

C. Turesson, R. McClelland, T. Christianson, 2006, Annals of the rheumatic diseases.

Malignancy as a comorbidity in rheumatic diseases.

C. Turesson, E. Matteson, 2013, Rheumatology.

The prevalence of moderate to severe radiographic sacroiliitis and the correlation with health status in elderly Swedish men – The MrOS study

I. Redlund‐Johnell, D. Mellström, C. Turesson, 2013, BMC Musculoskeletal Disorders.

Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations.

C. Turesson, E. Matteson, R. McClelland, 2006, Arthritis and rheumatism.

Genetics of rheumatoid arthritis: Is there a pattern predicting extraarticular manifestations?

C. Turesson, E. Matteson, C. Weyand, 2004, Arthritis and rheumatism.

Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians.

S. Pillemer, R. Hanson, P. Bennett, 2001, Arthritis and rheumatism.

Increased endothelial expression of HLA-DQ and interleukin 1alpha in extra-articular rheumatoid arthritis. Results from immunohistochemical studies of skeletal muscle.

C. Turesson, L. Jacobsson, L. Truedsson, 2001, Rheumatology.

COMP-C3b Complexes in Rheumatoid Arthritis with Severe Extraarticular Manifestations

C. Turesson, L. Jacobsson, A. Blom, 2013, The Journal of Rheumatology.

The Journal of Rheumatology ManifestationsCOMP-C3b Complexes in Rheumatoid Arthritis with Severe Extraarticular

C. Turesson, A. Blom, D. Heinegård, 2013 .

Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study

C. Turesson, X. Mariette, K. Pavelka, 2016, EBioMedicine.

Validity of ankylosing spondylitis and undifferentiated spondyloarthritis diagnoses in the Swedish National Patient Register

C. Turesson, J. Askling, L. Jacobsson, 2015, Scandinavian journal of rheumatology.

Comorbidity in rheumatoid arthritis.

C. Turesson, 2016, Swiss medical weekly.

Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis

C. Turesson, E. Matteson, G. Sturfelt, 2006, Annals of the rheumatic diseases.

The relation between upper extremity joint involvement and grip force in early rheumatoid arthritis: a retrospective study

C. Turesson, L. Jacobsson, M. Rydholm, 2019, Rheumatology International.

Tumor Necrosis Factor Inhibitors and Cancer Recurrence in Swedish Patients With Rheumatoid Arthritis

C. Turesson, J. Askling, P. Raaschou, 2018, Annals of Internal Medicine.

Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis.

C. Turesson, L. Jacobsson, P. Geborek, 2005, The Journal of rheumatology.

FRI0298 The Impact of DMARD Co-Therapy on Abatacept Effectiveness in Rheumatoid Arthritis Patients. A Pan-European Analysis of RA Registries

Helena Canhão, Xavier Mariette, C. Turesson, 2014 .

The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study

Lars Erik Kristensen, M. Neovius, C. Turesson, 2015, Arthritis Research & Therapy.

Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis

C. Turesson, L. Jacobsson, S. Jovinge, 2018, Current therapeutic research, clinical and experimental.

Management of extra-articular disease manifestations in rheumatoid arthritis

C. Turesson, E. Matteson, 2004, Current opinion in rheumatology.

Is there a future role for anti-TNF therapy in cardiovascular disease?

C. Turesson, L. Jacobsson, S. Jovinge, 2007 .

Smoking, low formal level of education, alcohol consumption, and the risk of rheumatoid arthritis

C. Turesson, L. Jacobsson, U. Bergström, 2013, Scandinavian journal of rheumatology.

An update on polymyalgia rheumatica

C. Turesson, I. Lundberg, A. Mohammad, 2022, Journal of internal medicine.

Citrullination in extra-articular manifestations of rheumatoid arthritis.

P Harle, C. Turesson, E. Matteson, 2007, Rheumatology.

Antibodies to modified citrullinated vimentin are associated with severe extra-articular manifestations in rheumatoid arthritis

C. Turesson, L. Jacobsson, G. Sturfelt, 2013, Annals of the rheumatic diseases.

Extra-articular rheumatoid arthritis

C. Turesson, 2013, Current opinion in rheumatology.

Predictors of extra-articular manifestations in rheumatoid arthritis.

C. Turesson, L. Truedsson, G. Sturfelt, 2000, Scandinavian journal of rheumatology.

The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries.

C. Turesson, X. Mariette, K. Pavelka, 2020, Rheumatology.

CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis.

C. Turesson, E. Matteson, M. Wasko, 2007, Arthritis and rheumatism.

Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis

C. Turesson, E. Matteson, R. McClelland, 2006, Annals of the rheumatic diseases.

Cardiovascular risk factors, fitness and physical activity in rheumatic diseases

C. Turesson, E. Matteson, 2007, Current opinion in rheumatology.

86 – Extraarticular features of rheumatoid arthritis and systemic involvement

C. Turesson, E. Matteson, 2014 .

Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmö, Sweden.

C. Turesson, L. Jacobsson, U. Bergström, 2009, Rheumatology.

Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis

C. Turesson, L. Jacobsson, P. Geborek, 2006, Annals of the rheumatic diseases.

, patients with rheumatoid arthritis Treatment with TNF blockers and mortality risk in

C. Turesson, L. Jacobsson, P. Geborek, 2007 .

Nitrosative modifications of the Ca2+ release complex and actin underlie arthritis-induced muscle weakness

H. Westerblad, C. Turesson, F. Minozzo, 2014, Annals of the rheumatic diseases.

Association of Rheumatoid Factor and Anti–Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis

C. Turesson, X. Mariette, K. Pavelka, 2016 .

Incidence of Extraarticular Rheumatoid Arthritis in Olmsted County, Minnesota, in 1995–2007 Versus 1985–1994: A Population-based Study

S. Gabriel, C. Turesson, E. Matteson, 2011, The Journal of Rheumatology.

Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register

C. Turesson, L. Jacobsson, S. Saevarsdottir, 2020, Arthritis research & therapy.

Lower extremity function in patients with early rheumatoid arthritis during the first five years, and relation to other disease parameters

C. Turesson, L. Jacobsson, S. Hagel, 2019, Scandinavian journal of rheumatology.

Early menopause and severity of rheumatoid arthritis in women older than 45 years

C. Turesson, L. Jacobsson, J. Nilsson, 2012, Arthritis Research & Therapy.

Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia.

C. Turesson, E. Matteson, J. Ryu, 2006, Arthritis and rheumatism.

Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis.

C. Turesson, E. Matteson, T. Colby, 2005, Arthritis and rheumatism.

A more active treatment has profound effects on the health status of rheumatoid arthritis (RA) patients: results from a population-based RA register in Malmö, Sweden, 1997–2005

C. Turesson, L. Jacobsson, Y. Lindroth, 2010, Scandinavian journal of rheumatology.

Breast feeding, but not use of oral contraceptives, is associated with a reduced risk of rheumatoid arthritis

G. Berglund, C. Turesson, J. Nilsson, 2008, Annals of the rheumatic diseases.

The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis

D. Schaid, C. Turesson, L. Jacobsson, 2005, Arthritis research & therapy.

EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry

C. Turesson, H. Bliddal, M. Englund, 2017, PloS one.

The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden in 2017

C. Turesson, L. Jacobsson, J. Askling, 2023, The Journal of Rheumatology.

Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis.

D. Schaid, C. Turesson, L. Jacobsson, 2006, Arthritis and rheumatism.

Vasculitis in rheumatoid arthritis

C. Turesson, E. Matteson, 2009, Current opinion in rheumatology.

Increased stiffness of the abdominal aorta in women with rheumatoid arthritis.

C. Turesson, G. Sturfelt, T. Länne, 2005, Rheumatology.

Changes in bone mineral density over 10 years in patients with early rheumatoid arthritis

C. Turesson, L. Jacobsson, J. Nilsson, 2020, RMD Open.

Validity of polymyalgia rheumatica diagnoses and classification criteria in primary health care

C. Turesson, U. Bergström, M. Willim, 2019, Rheumatology advances in practice.

No increase of severe infections in RA patients treated with TNF-blockers

C. Turesson, L. Jacobsson, P. Geborek, 2005 .

SAT0098 Validity of Ankylosing Spondylitis and Spondyloarthritis Diagnoses in the Swedish National Patient Register

C. Turesson, J. Askling, L. Kristensen, 2014 .

A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission

C. Turesson, E. Lindqvist, R. V. van Vollenhoven, 2016, RMD Open.

Joint tenderness at 3 months follow-up better predicts long-term pain than baseline characteristics in early rheumatoid arthritis patients.

C. Turesson, S. Bergman, T. Mandl, 2023, Rheumatology.

Endothelial expression of MHC class II molecules in autoimmune disease.

C. Turesson, 2004, Current pharmaceutical design.

Comment on: Epidemiology of biopsy-confirmed giant cell arteritis in southern Sweden—an update on incidence and first prevalence estimate: reply

C. Turesson, M. Englund, A. Turkiewicz, 2021, Rheumatology.

Signs of systemic disease are strong determinants of mortality in rheumatoid arthritis: comment on the article by Navarro-Cano et al.

C. Turesson, E. Matteson, 2004, Arthritis and rheumatism.

The impact of HLA-DRB 1 genes on extra-articular disease manifestations in rheumatoid arthritis

D. Schaid, C. Turesson, L. Jacobsson, 2005 .

Radiographic damage in early rheumatoid arthritis is associated with increased disability but not with pain—a 5-year follow-up study

C. Turesson, S. Bergman, T. Mandl, 2023, Arthritis Research & Therapy.

Local Organising Committee

R. Nisell, C. Turesson, L. Jacobsson, 2002 .

LOCAL ORGANISING COMMITTEE

R. Nisell, C. Turesson, L. Jacobsson, 2013 .

Autoantibodies in Rheumatoid Arthritis - Laboratory and Clinical Perspectives.

C. Turesson, A. Kastbom, J. Rönnelid, 2021, Frontiers in immunology.

Genome-wide investigation of persistence with methotrexate treatment in early rheumatoid arthritis

K. Stefánsson, I. Jónsdóttir, C. Turesson, 2023, Rheumatology.

Analyses of plasma inflammatory proteins reveal biomarkers predictive of subsequent development of giant cell arteritis: a prospective study

C. Turesson, E. Matteson, K. Warrington, 2022, Rheumatology.

Comment on: Negative associations for fasting blood glucose, cholesterol and triglyceride levels with the development of giant cell arteritis: reply

C. Turesson, L. Jacobsson, E. Matteson, 2021, Rheumatology.

The Relation Between Disease Activity, Patient‐Reported Outcomes, and Grip Force Over Time in Early Rheumatoid Arthritis

C. Turesson, L. Jacobsson, M. Rydholm, 2019, ACR open rheumatology.

FRI0322 Positivity for Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide is Associated with A Better Drug Retention of Abatacept: Data from A Paneuropean Analysis of RA Registries

C. Turesson, X. Mariette, K. Pavelka, 2014 .

Extra-articular rheumatoid arthritis: prevalence and mortality.

C. Turesson, L. Jacobsson, U. Bergström, 1999, Rheumatology.

Comorbidity in rheumatoid arthritis.

C. Turesson, 2016, Swiss medical weekly.

Extra-articular rheumatoid arthritis

C. Turesson, 2013, Current opinion in rheumatology.

Rheumatoid factor and anti-citrullinated protein antibody positivity are associated with a better effectiveness of abatacept: Results from the Pan-European registry analysis.

C. Turesson, A. Finckh, M. Hetland, 2016 .

Cardiovascular disease risk in early rheumatoid arthritis: the impact of cartilage oligomeric matrix protein (COMP) and disease activity

C. Turesson, E. Rydell, Lennart Jacobsson, 2023, BMC Rheumatology.

Lower Frequency of Comorbidities Prior to Onset of Giant Cell Arteritis: A Population-Based Study

C. Turesson, E. Matteson, S. Achenbach, 2022, The Journal of Rheumatology.

Methotrexate use among men-association with fertility and the perinatal health of their children: a Swedish nationwide register study.

C. Turesson, A. Giwercman, P. Zarén, 2023, Fertility and sterility.

Course of Grip Force Impairment in Patients With Early Rheumatoid Arthritis Over the First Five Years After Diagnosis

C. Turesson, L. Jacobsson, C. Book, 2018, Arthritis care & research.

Proteomic Data Analysis for Differential Profiling of the Autoimmune Diseases SLE, RA, SS, and ANCA-Associated Vasculitis

C. Turesson, M. Ohlsson, E. Theander, 2020, Journal of proteome research.

Apolipoproteins and the risk of giant cell arteritis—a nested case–control study

C. Turesson, E. Matteson, K. Warrington, 2024, Arthritis research & therapy.

Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b/tsDMARDs in Sweden

C. Turesson, B. Delcoigne, H. Forsblad-d’Elia, 2023, RMD Open.

Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study

C. Turesson, L. Jacobsson, Anders Jarenros, 2004, Annals of the rheumatic diseases.

C. Turesson, L. Jacobsson, L. Theander, 2023, BMC Rheumatology.

Predictors at diagnosis for start of biologic disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis: a cohort study

C. Turesson, U. Bergström, S. Exarchou, 2024, BMJ Open.

Validity of ankylosing spondylitis and undifferentiated spondyloarthritis diagnoses in the Swedish National Patient Register

C. Turesson, L. Jacobsson, U. Lindström, 2015, Scandinavian journal of rheumatology.

Adherence to dietary guidelines, and the risk of developing rheumatoid arthritis: results from a nested case-control study

C. Turesson, E. Sonestedt, U. Bergström, 2023, Rheumatology.

The relation between synovitis of individual finger joints and grip force over the first 5 years in early rheumatoid arthritis — a cohort study

C. Turesson, M. Rydholm, Lennart Jacobsson, 2023, Arthritis Research & Therapy.

Temporal artery biopsy in giant cell arteritis: clinical perspectives and histological patterns

C. Turesson, A. Mohammad, P. Stamatis, 2024, Frontiers in medicine.

Myocardial infarction in a population-based cohort of patients with biopsy-confirmed giant cell arteritis in southern Sweden

C. Turesson, M. Mohammad, A. Mohammad, 2024, RMD open.

Biopsy findings in giant cell arteritis: relationship to baseline factors and corticosteroid treatment

C. Turesson, K. Warrington, E. Matteson, 2013, Scandinavian journal of rheumatology.